India Pharma Outlook Team | Wednesday, 14 October 2026
Johnson & Johnson advances Ortho breakup plans as shares come under pressure.
The healthcare giant beats earnings estimates yet faces a drag from medical device sales.
Management signals a clear preference for spinning out the hips-and-knees business rather than pursuing other paths.
This stance builds on earlier intentions to separate the orthopedics unit and aims to unlock shareholder value.
Strong pharmaceutical performance, led by key treatments, drives the overall beat while international headwinds weigh on devices.
Investors watch this separation closely as the company raises its full-year outlook and navigates geopolitical pressures that reshape regional budgets.
Johnson & Johnson posted third-quarter revenue of USD 25.4 billion, which topped analysts’ average estimate of USD 25.28 billion. Adjusted earnings reached USD 2.59 per share and exceeded Wall Street expectations of USD 2.54.
Pharmaceutical sales jumped 7.7 percent to USD 16.76 billion. Key products delivered robust results:
Tremfya has increasingly replaced lost Stelara revenue after recent approvals in inflammatory bowel diseases.
The company raised its full-year forecast for reported sales to about USD 101.2 billion at the midpoint, up from USD 101.1 billion. It also lifted the adjusted earnings midpoint to USD 11.10 per share from USD 11.04.
Also Read: 15 Pharma Marketing KPIs Indian Companies Should Track in 2026
Medical technology division sales rose only 2.5 percent to USD 8.6 billion overall. Outside the United States, sales in the division stayed basically flat.
Chief Financial Officer Joe Wolk noted that the Middle East conflict, austerity measures in Europe, and pricing in China continued to weigh on international results, and the impact appeared more pronounced. The conflict has yet to affect company costs but has hurt sales in the region. Countries such as Kuwait, the UAE, and Saudi Arabia still value premium healthcare systems, yet their budgets now shift toward defense.
Sales at the Abiomed heart pump business remained slow after a UK study earlier this year raised questions about the use of Impella pumps during certain high-risk coronary procedures.
Shares of the company fell more than 2 percent before the bell. J&J shares closed at USD 263.73 on Monday and have risen 27 percent this year, outperforming the broader market and most healthcare peers.
The company had said late last year it intended to separate its orthopedics unit. J&J is leaning toward spinning out its hips-and-knees business, Wolk told the Wall Street Journal.
This preference positions the spin as the path management favors for creating long-term value. The move follows the company’s earlier decision to pursue separation and keeps the orthopedics business on track for independent status. A pure-play structure would allow the unit to operate with focused attention while the parent concentrates on higher-growth areas.
Together, the earnings strength in pharmaceuticals, the pressure on medical devices, and the renewed emphasis on the orthopedics separation paint a picture of deliberate portfolio refinement. J&J continues to advance its breakup plans even as share price reacts to the mixed quarterly signals.
.jpg)
